Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer’s Disease
- 465 Downloads
To date, we still lack disease-modifying therapies for Alzheimer’s disease (AD). Here, we report that long-term administration of benfotiamine improved the cognitive ability of patients with AD. Five patients with mild to moderate AD received oral benfotiamine (300 mg daily) over 18 months. All patients were examined by positron emission tomography with Pittsburgh compound B (PiB-PET) and exhibited positive imaging with β-amyloid deposition, and three received PiB-PET imaging at follow-up. The five patients exhibited cognitive improvement as assayed by the Mini-Mental Status Examination (MMSE) with an average increase of 3.2 points at month 18 of benfotiamine administration. The three patients who received follow-up PiB-PET had a 36.7% increase in the average standardized uptake value ratio in the brain compared with that in the first scan. Importantly, the MMSE scores of these three had an average increase of 3 points during the same period. Benfotiamine significantly improved the cognitive abilities of mild to moderate AD patients independently of brain amyloid accumulation. Our study provides new insight to the development of disease-modifying therapy.
KeywordsAlzheimer’s disease Therapy Benfotiamine PiB-PET Amyloid deposition
This work was supported by the Key Fund for Developing New Drugs from the Ministry of Science and Technology of China (2014ZX09101005-005), the National Natural Science Foundation of China (81071019), the National Key Basic Research Program of China (2011CBA00400), the Natural Science Foundation of Shanghai Municipality, China (13JC1401500), and the Fund for Medical Emerging Cutting-Edge Technology in Shanghai of China (SHDC12012114). We thank Dr. Mu-ming Poo (Institute of Neuroscience, State Key Laboratory of Neuroscience, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences) for his valuable insight and critique of the article. We also thank Dr. Alexandra H. Marshal (Department of Laboratory Medicine and Pathobiology, St. Michael’s Hospital, University of Toronto) for her careful editing of the article. We gratefully acknowledge all of the participants for their contributions to this study.
- 19.McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011, 7: 263–269.CrossRefPubMedPubMedCentralGoogle Scholar